** Shares of drug developer NeuroBo Pharmaceuticals rise 3.3% to $3.43 premarket
** Co says its obesity drug was found to be safe and well tolerated and did not result in any serious adverse effects in an early-stage study conducted with 45 obese, otherwise healthy individuals
** The main goal of the study was to assess the safety and tolerability of the drug by monitoring adverse events
** Five subjects receiving the treatment reported adverse events vs 3 subjects in the placebo group - NRBO says
** As of last close, stock down 10.2% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。